School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.
Acta Biomater. 2018 Aug;76:1-20. doi: 10.1016/j.actbio.2018.03.043. Epub 2018 Apr 4.
Cell-free (CF) protein synthesis has emerged as a powerful technique platform for efficient protein production in vitro. Liposomes have been widely studied as therapeutic carriers due to their biocompatibility, biodegradability, low toxicity, flexible surface manipulation, easy preparation, and higher cargo encapsulation capability. However, rapid immune clearance, insufficient targeting capacity, and poor cytoplasmic delivery efficiency substantially restrict their clinical application. The incorporation of functional membrane proteins (MPs) or peptides allows the transfer of biological properties to liposomes and imparts them with improved circulation, increased targeting, and efficient intracellular delivery. Liposome-chaperoned CF synthesis enables production of proteoliposomes in one-step reaction, which not only substantially simplifies the production procedure but also keeps protein functionality intact. Building off these observations, proteoliposomes with integrated MPs represent an excellent candidate for therapeutic delivery. In this review, we describe recent advances in CF synthesis with emphasis on detailing key factors for improving CF expression efficiency. Furthermore, we provide insights into strategies for rational design of proteoliposomal nanodelivery systems via CF synthesis.
Liposome-chaperoned CF synthesis has emerged as a powerful approach for the design of recombinant proteoliposomes in one-step reaction. The incorporation of bioactive MPs or peptides into liposomes via CF synthesis can facilitate the development of proteoliposomal nanodelivery systems with improved circulation, increased targeting, and enhanced cellular delivery capacity. Moreover, by adapting lessons learned from natural delivery vehicles, novel bio-inspired proteoliposomes with enhanced delivery properties could be produced in CF systems. In this review, we first give an overview of CF synthesis with focus on enhancing protein expression in liposome-chaperoned CF systems. Furthermore, we intend to provide insight into harnessing CF-synthesized proteoliposomes for efficient therapeutic delivery.
无细胞(CF)蛋白质合成已成为体外高效蛋白质生产的强大技术平台。由于其生物相容性、生物可降解性、低毒性、灵活的表面处理、易于制备和更高的货物封装能力,脂质体已被广泛研究为治疗载体。然而,快速的免疫清除、不足的靶向能力和较差的细胞质递送效率极大地限制了它们的临床应用。功能性膜蛋白(MPs)或肽的掺入允许将生物特性转移到脂质体上,并赋予其改善的循环、增加的靶向和有效的细胞内递送。脂质体伴随的 CF 合成使在一步反应中生产蛋白脂质体成为可能,这不仅大大简化了生产过程,而且保持了蛋白质的功能完整性。基于这些观察结果,具有整合 MPs 的蛋白脂质体代表了治疗传递的优秀候选物。在这篇综述中,我们描述了 CF 合成的最新进展,重点详细介绍了提高 CF 表达效率的关键因素。此外,我们还提供了通过 CF 合成合理设计蛋白脂质体纳米递药系统的策略见解。
脂质体伴随的 CF 合成已成为一步反应中设计重组蛋白脂质体的强大方法。通过 CF 合成将生物活性 MPs 或肽掺入脂质体中,可以促进具有改善的循环、增加的靶向和增强的细胞递送能力的蛋白脂质体纳米递药系统的发展。此外,通过从天然递药载体中吸取经验教训,可以在 CF 系统中产生具有增强的递药特性的新型仿生蛋白脂质体。在这篇综述中,我们首先概述了 CF 合成,重点是提高脂质体伴随的 CF 系统中蛋白质的表达。此外,我们旨在提供对利用 CF 合成的蛋白脂质体进行有效治疗传递的见解。